GlycoMimetics, Inc. (GLYC) Financial Statements (2024 and earlier)

Company Profile

Business Address 9708 MEDICAL CENTER DRIVE
ROCKVILLE, MD 20850
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments58,03765,00247,87151,62560,24476,516
Cash and cash equivalents58,03765,00247,87151,62560,24476,516
Receivables215234144901215
Prepaid expense1,3622,2912,3001,622293460
Other undisclosed current assets754559400511606483
Total current assets:60,36968,08750,71553,84861,26477,464
Noncurrent Assets
Operating lease, right-of-use asset1,1835327519651,1741,377
Property, plant and equipment168201242288333350
Prepaid expense5050508082,2212,221
Other undisclosed noncurrent assets525252525252
Total noncurrent assets:1,4538351,0962,1133,7804,001
TOTAL ASSETS:61,82268,92251,81155,96165,04481,465
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,7526,0887,9628,82310,27811,753
Employee-related liabilities2,1592,396
Accounts payable2414809708521,2712,276
Accrued liabilities5,5105,6086,9925,8126,6119,477
Other undisclosed current liabilities820652919(1,075)(1,340)1,029
Total current liabilities:6,5726,7408,8817,7488,93812,782
Noncurrent Liabilities
Long-term debt and lease obligation:    96379652
Liabilities, other than long-term debt449     
Operating lease, liability449  96379652
Other undisclosed noncurrent liabilities    (96)(379)(652)
Total noncurrent liabilities:449  96379652
Total liabilities:7,0216,7408,8817,8449,31713,434
Equity
Equity, attributable to parent54,80162,18142,93048,11855,72768,031
Common stock646454525252
Additional paid in capital492,940492,062462,461457,407456,493455,529
Accumulated deficit(438,204)(429,945)(419,586)(409,341)(400,818)(387,550)
Total equity:54,80162,18142,93048,11855,72768,031
TOTAL LIABILITIES AND EQUITY:61,82268,92251,81155,96165,04481,465

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues     75 
Gross profit:     75 
Operating expenses(8,930)(10,941)(10,623)(8,767)(13,428)(14,660)
Operating loss:(8,930)(10,941)(10,623)(8,767)(13,353)(14,660)
Loss from continuing operations:(8,930)(10,941)(10,623)(8,767)(13,353)(14,660)
Loss before gain (loss) on sale of properties:(8,767)(13,353)(14,660)
Other undisclosed net income  582378  7
Net loss:(8,930)(10,359)(10,244)(8,767)(13,353)(14,653)
Other undisclosed net income attributable to parent671  24486 
Net loss available to common stockholders, diluted:(8,259)(10,359)(10,244)(8,524)(13,268)(14,653)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(8,930)(10,359)(10,244)(8,767)(13,353)(14,653)
Comprehensive loss, net of tax, attributable to parent:(8,930)(10,359)(10,244)(8,767)(13,353)(14,653)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: